CORE srl-Collaborative Outcome Research, Via Magnanelli 2, 40033 Casalecchio di Reno, Bologna, Italy.
Health Care Department, CINECA-Interuniversity Consortium, Casalecchio di Reno, Bologna, Italy.
Neurol Sci. 2018 Jul;39(7):1169-1174. doi: 10.1007/s10072-018-3404-4. Epub 2018 Apr 10.
Epidemiological data on primary progressive multiple sclerosis (PPMS) are scarce. This study was aimed to evaluate the burden of PPMS in Italy with healthcare resources utilisation and costs for Italian National Health System (INHS). A 2-year cross-sectional analysis of real-world data collected in the ARCO database, covering > 10 million Italian inhabitants, was performed. From a cohort of patients affected by MS in 2014, those supposedly affected by PPMS were defined by the concurrent matching of absence of disease-modifying treatments and use of rehabilitation services. Any other drug prescriptions, outpatient services and hospitalisations were analysed in 2015 for each subject. The average annual cost per patient was provided both for each expenditure item and by integrating these. Of 13,253,591 inhabitants, 18,453 resulted affected by MS (prevalence 139 × 100,000). Of these, 1849 agreed with additional criteria to identify PPMS (10% of MS population). The 26.8% of these experienced at least one admission in 1 year, 97.3% used at least one outpatient service and 94.3% received at least one reimbursed drug. In the perspective of INHS, PPMS generated an average annual cost of € 3783 per person: 49% for hospitalisations, 28% for outpatient services and 23% for drugs. This study provides a reliable estimation of the PPMS burden in Italy, in terms of healthcare utilisation and direct costs. These findings could be useful to estimate the changes in health expenditure following the incoming of new drugs to treat PPMS with increase of pharmaceutical cost and potential decrease of rehabilitation and hospitalisation costs.
原发性进展型多发性硬化症(PPMS)的流行病学数据较为匮乏。本研究旨在评估意大利 PPMS 的疾病负担,分析意大利国家卫生系统(INHS)的医疗资源利用和成本情况。本研究通过 ARCO 数据库收集了 2014 年超过 1000 万意大利居民的真实世界数据,采用了为期 2 年的回顾性横断面分析。在这一队列中,对患有 MS 的患者进行分析,同时考虑到缺乏疾病修正治疗和使用康复服务,将这些患者定义为可能患有 PPMS 的患者。对每位患者,在 2015 年分析了其他任何药物处方、门诊服务和住院情况。按每个支出项目和整合这些项目分别提供每位患者的平均年度费用。在 1325.3591 万居民中,有 18453 人患有 MS(发病率为 139×100000)。其中,1849 人符合识别 PPMS 的附加标准(MS 人群的 10%)。在这些患者中,26.8%的患者在 1 年内至少经历过一次住院治疗,97.3%的患者至少使用过一次门诊服务,94.3%的患者至少接受过一种报销药物。从 INHS 的角度来看,PPMS 每人每年产生 3783 欧元的平均费用:49%用于住院治疗,28%用于门诊服务,23%用于药物治疗。本研究提供了意大利 PPMS 负担的可靠估计,包括医疗资源利用和直接成本。这些发现可能有助于估计随着治疗 PPMS 的新药的引入,医疗支出的变化,从而增加药品成本和潜在降低康复和住院成本。